

Future Directions in the Management of Aortic Coarctation in Young Patients

P Syamasundar Rao*

Department of Pediatrics and Medicine, University of Texas-Houston Medical School, USA

***Corresponding author:** P Syamasundar Rao, Professor, Department of Pediatrics and Medicine, Emeritus Chief of Pediatric Cardiology, University of Texas-Houston Medical School, Children's Memorial Hermann Hospital, Houston, Texas, 6410 Fannin Street, UTPB Suite # 425. Houston, TX 77030, USA, Tel: 713-500-5738; Fax: 713-500-5751; E-mail: P.Syamasundar.Rao@uth.tmc.edu

Rec date: Nov 5, 2014, **Acc date:** Nov 7, 2014, **Pub date:** Nov 10, 2014

Copyright: © 2014 Rao PS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Coarctation of the aorta (COA) is a congenital anomaly of the heart in which the descending aorta is obstructed. The narrowed aortic segment comprises of localized medial thickening along with infolding of the media and neointimal tissue [1-3]. The COA constitutes 5-8% of all babies born with congenital heart disease [4,5].

The management of COA was by surgical repair since its initial description by Crafoord and Nylin [6] and Gross [7] in mid 1940s. More recently, endovascular therapy either by balloon angioplasty [3,8-10] or intravascular stents [3,11-13] has to a large extent replaced surgery. Surgery in the neonates and young infants, balloon angioplasty in children and stents in adolescents and adults have become standard methods used in the management of COA [3,14-16]. However, recoarctation following both surgery [17-19] and balloon angioplasty [15,20,21] has been observed; the younger the child, the greater is the probability of recoarctation. Presumably because of this recurrence, some groups of cardiologists advocate use of stents even in infants and young children [11,22-28]. However, the stents, which are largely metallic, do not expand as the child grows; this is particularly true in the neonates, infants and young children, as has been articulated elsewhere [29-31] by us and others. While re-dilatation of the stents can be performed, such re-enlargement may not achieve adult size [32]. Therefore, alternative solutions [29,30,33,34] should be sought. Three types of solutions have been considered in the past and include biodegradable stents, growth stents and dilatable stents.

Biodegradable Stents

The concept for using biodegradable stent is that they open the coarcted aortic segment at implantation and dissolve over the next few months. They may be constructed with polycarbonates, polyesters, bacterial-derived polymers, or corrodible metals [35-37], mounted on balloons and trans-catheter implanted across the COA. The scaffolding left over by the dissolving stent may allow normal aortic tissue to grow and prevent significant recoarctation. Such a concept has been, though to a limited extent, tested in animal models [38,39]. Additional animal experimentation to examine issues such as mechanical stability including radial strength, body's inflammatory response and possible toxicity of the dissolving stent material should be undertaken followed by clinical trials to establish feasibility, safety and efficacy of such an approach. Report of utility of a bioabsorbable metal stent in a neonate with critical recoarctation [40] is a step in the right direction. However, clinical trials in large groups of infants and young children with COA are mandatory prior to adopting this mode of therapy. Furthermore, stent delivery systems should also be made small enough to be useful in neonates and young infants.

Growth Stents

To address the growth issue with the conventional stents, several investigators either cut open the stents longitudinally or construct two separate half stents and connected them with absorbable or thin Prolene suture material; such modifications have been described as open-ring [41] growth [42] or breakable [43] stents by the respective investigators. Implantation of these stents into blood vessels including the aorta of piglets and dilatation of these stents at follow-up was shown to be feasible by these investigators. Ewert and his colleagues [44] extended this concept to human subjects by implanting the growth stents in infants with aortic coarctation. The growth stents used by Ewert are made-up of two longitudinal halves of laser-cut 0.16 mm stainless steel connected to each other with absorbable, Polydioxanone suture material. The stents were mounted on 4 to 8 mm diameter angioplasty balloon catheters and were implanted via 5-French sheaths. Following implantation of the growth stents in 12 infants at a median age of 5 months, the mean gradient fell from 30 mmHg to 8 mmHg. At a median follow-up of 3 to 28 months, five patients required balloon re-dilatation of the initially placed growth stent. Six patients had larger stents implanted 19 to 34 months after initial stent placement. The authors conclude that growth stent is suitable for management of aortic coarctation in infants. However, the overall results may not be satisfactory since multiple interventions were required. Clinical trials in larger number of subjects may be necessary to demonstrate the usefulness of this concept and utility of this technique.

Dilatable Stents

If the stents implanted in neonates, infants and young children could later be dilated to 20 mm or more (adult size), such stents may have utility. Recent report by Shepherd and associates [45] of implantation of Valeo Biliary Pre-mounted Re-dilatable Stent (Edwards Life Sciences, California, USA) via a 7-French sheath in a 3-year-old child with COA is encouraging. Although not yet done, the authors state that this stent can be dilated up to 20 mm. Ready accessibility of such stents, particularly if they can be implanted via small sheaths may largely resolve growth issues related to stents in infants and young children.

Summary and Conclusions

Coarctations in neonates, infants and young children have high incidence of recurrence whether they are treated by surgery or by balloon angioplasty. Therefore, stents may help avert such a problem; unfortunately however, the stents do not grow as the child grows. Consequently, innovations such as bioabsorbable, growth and dilatable stents should be explored in the future.

References

1. Rao PS (1995) Coarctation of the aorta. In: *Secondary Forms of Hypertension*, Ram CVS (ed), *Seminars in Nephrology*, Kurtzman NA (ed), W.B. Saunders, Philadelphia, PA 15: 81-105.
2. Rao PS (2005) Coarctation of the aorta. *Curr Cardiol Rep* 7: 425-434.
3. Rao PS, Seib PM (2014) *Coarctation of the Aorta*. Medscape Reference.
4. Nadas AS, Fyler DC (1972) *Pediatric Cardiology*. Philadelphia, PA, Saunders 3: 683.
5. Keith JD, Rowe RD, Vlad P (1978) *Heart Disease in Infancy and Childhood*. New York, NY, Macmillan 3: 4-6.
6. Crafoord O, Nylin G (1945) Congenital coarctation of the aorta and its surgical treatment. *J Thorac Cardiovasc Surg* 14: 347-361.
7. Gross RE (1945) Surgical correction for coarctation of the aorta. *Surgery* 18: 673-678.
8. Tynan M, Finley JP, Fontes V, Hess J, Kan J (1990) Balloon angioplasty for the treatment of native coarctation: results of Valvuloplasty and Angioplasty of Congenital Anomalies Registry. *Am J Cardiol* 65: 790-792.
9. Rao PS (1993) Balloon angioplasty of native aortic coarctation in Rao PS (ed): *Transcatheter Therapy in Pediatric Cardiology*. Wiley-Liss, New York, NY 153-196.
10. Rao PS (1995) Should balloon angioplasty be used instead of surgery for native aortic coarctation? *Br Heart J* 74: 578-579.
11. Suárez de Lezo J, Pan M, Romero M, Medina A, Segura J, et al. (1995) Balloon-expandable stent repair of severe coarctation of aorta. *Am Heart J* 129: 1002-1008.
12. Rao PS (1997) Stents in treatment of aortic coarctation. *J Am Coll Cardiol* 30: 1853-1855.
13. Rao PS (2001) Stents in the management of congenital heart disease in pediatric and adult patients. *Indian Heart J* 53: 714-730.
14. Rao PS (1989) Which aortic coarctations should we balloon-dilate? *Am Heart J* 117: 987-989.
15. Rao PS, Galal O, Smith PA, Wilson AD (1996) Five- to nine-year follow-up results of balloon angioplasty of native aortic coarctation in infants and children. *J Am Coll Cardiol* 27: 462-470.
16. Doshi AR, Rao PS (2012) Coarctation of aorta-Management options and decision making. *Pediatr Therapeut* 5: 006.
17. Pinzon JL, Burrows PE, Benson LN, Moës CA, Lightfoot NE, et al. (1991) Repair of coarctation of the aorta in children: postoperative morphology. *Radiology* 180: 199-203.
18. Rao PS (1993) Balloon angioplasty of aortic recoarctation following previous surgery. In: Rao PS (ed) *Transcatheter Therapy in Pediatric Cardiology*, Wiley-Liss, New York, NY 197-212.
19. Rao PS, Thapar MK, Kutayli F, Carey P (1989) Causes of recoarctation after balloon angioplasty of unoperated aortic coarctation. *J Am Coll Cardiol* 13: 109-115.
20. Kaine SF, Smith EO, Mott AR, Mullins CE, Geva T (1996) Quantitative echocardiographic analysis of the aortic arch predicts outcome of balloon angioplasty of native coarctation of the aorta. *Circulation* 94: 1056-1062.
21. Redington AN, Hayes AM, Ho SY (1993) Transcatheter stent implantation to treat aortic coarctation in infancy. *Br Heart J* 69: 80-82.
22. Suárez de Lezo J, Pan M, Romero M, Medina A, Segura J, et al. (1999) Immediate and follow-up findings after stent treatment for severe coarctation of aorta. *Am J Cardiol* 83: 400-406.
23. Al-Ata J, Arfi AM, Hussain A, Kouatly A, Galal MO (2007) Stent angioplasty: an effective alternative in selected infants with critical native aortic coarctation. *Pediatr Cardiol* 28: 183-192.
24. Schaeffler R, Kolax T, Hesse C, Peuster M (2007) Implantation of stents for treatment of recurrent and native coarctation in children weighing less than 20 kilograms. *Cardiol Young* 17: 617-622.
25. Zanjani KS, Sabi T, Moysich A, Ovroutski S, Peters B, et al. (2008) Feasibility and efficacy of stent redilatation in aortic coarctation. *Catheter Cardiovasc Interv* 72: 552-556.
26. Francis E, Gayathri S, Vaidyanathan B, Kannan BR, Kumar RK (2009) Emergency balloon dilation or stenting of critical coarctation of aorta in newborns and infants: An effective interim palliation. *Ann Pediatr Cardiol* 2: 111-115.
27. Mohan UR, Danon S, Levi D, Connolly D, Moore JW (2009) Stent implantation for coarctation of the aorta in children <30 kg. *JACC Cardiovasc Interv* 2: 877-883.
28. Mullins CE (2008) Inappropriate stents: primary cause of failure of stent redilatation in coarctation of the aorta. *Catheter Cardiovasc Interv* 72: 557-558.
29. Rao PS (2009) Transcatheter interventions in critically ill neonates and infants with aortic coarctation. *Ann Pediatr Cardiol* 2: 116-119.
30. Rao PS (2009) Stents in the management of aortic coarctation in young children. *JACC Cardiovasc Interv* 2: 884-886.
31. Hager A, Schreiber C, Nutzl S, Hess J (2009) Mortality and restenosis rate of surgical coarctation repair in infancy: a study of 191 patients. *Cardiology* 112: 36-41.
32. Duke C, Rosenthal E, Qureshi SA (2003) The efficacy and safety of stent redilatation in congenital heart disease. *Heart* 89: 905-912.
33. Rao PS (2001) Current status of balloon angioplasty for neonatal and infant aortic coarctation. *Progress Pediatr Cardiol* 14: 35-44.
34. Rao PS, Jureidini SB, Balfour IC, Singh GK, Chen SC (2003) Severe aortic coarctation in infants less than 3 months: successful palliation by balloon angioplasty. *J Invasive Cardiol* 15: 202-208.
35. Tanguay JF, Zidar JP, Phillips HR 3rd, Stack RS (1994) Current status of biodegradable stents. *Cardiol Clin* 12: 699-713.
36. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, et al. (2000) Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. *Circulation* 102: 399-404.
37. Waksman R, Pakala R (2010) Biodegradable and bioabsorbable stents. *Curr Pharm Des* 16: 4041-4051.
38. Bünger CM, Grabow N, Sternberg K, Goosmann M, Schmitz KP, et al. (2007) A biodegradable stent based on poly(L-lactide) and poly(4-hydroxybutyrate) for peripheral vascular application: preliminary experience in the pig. *J Endovasc Ther* 14: 725-733.
39. Veeram Reddy SR, Welch TR, Wang J, Richardson JA, Forbess JM, et al. (2014) A novel design biodegradable stent for use in congenital heart disease: Mid-term results in rabbit descending aorta. *Catheter Cardiovasc Interv*.
40. Schranz D, Zartner P, Michel-Behnke I, Akintürk H (2006) Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newborn. *Catheter Cardiovasc Interv* 67: 671-673.
41. Ing FF, Fagan TE, Kearney DL (1998) A new "open-ring" stent (Abstract). *Circulation* 94: 1-57.
42. Ewert P, Riesenkampff E, Neuss M, Kretschmar O, Nagdyman N, et al. (2004) Novel growth stent for the permanent treatment of vessel stenosis in growing children: an experimental study. *Catheter Cardiovasc Interv* 62: 506-510.
43. Sigler M, Schneider K, Meissler M, Koenig K, Schneider MB (2006) Breakable stent for interventions in infants and neonates: an animal study and histopathological findings. *Heart* 92: 245-248.
44. Ewert P, Peters B, Nagdyman N, Miera O, Kühne T, et al. (2008) Early and mid-term results with the Growth Stent--a possible concept for transcatheter treatment of aortic coarctation from infancy to adulthood by stent implantation? *Catheter Cardiovasc Interv* 71: 120-126.
45. Shepherd E, Connolly GM, Morgan G (2013) Using the Valeo dilatable stent in coarctation stenting for small children: expanding the inclusion criteria for coarctation stenting? *BMJ Case Rep* 2013.